Related references
Note: Only part of the references are listed.A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma
R. Nicolle et al.
ANNALS OF ONCOLOGY (2021)
Purity Independent Subtyping of Tumors (PurIST), A Clinically Robust, Single-sample Classifier for Tumor Subtyping in Pancreatic Cancer
Naim U. Rashid et al.
CLINICAL CANCER RESEARCH (2020)
Patient-derived xenograft models-the future of personalised cancer treatment
Jenna Bhimani et al.
BRITISH JOURNAL OF CANCER (2020)
GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer
Grainne M. O'Kane et al.
CLINICAL CANCER RESEARCH (2020)
Pancreatic cancer-derived organoids - a disease modeling tool to predict drug response
Pierre-Olivier Frappart et al.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2020)
Patient-Derived Xenograft Models of Pancreatic Cancer: Overview and Comparison with Other Types of Models
Patrick L. Garcia et al.
CANCERS (2020)
Evidencing a Pancreatic Ductal Adenocarcinoma Subpopulation Sensitive to the Proteasome Inhibitor Carfilzomib
Nicolas A. Fraunhoffer et al.
CLINICAL CANCER RESEARCH (2020)
Basal-like and classical cells coexist in pancreatic cancer revealed by single-cell analysis on biopsy-derived pancreatic cancer organoids from the classical subtype
Natalia Juiz et al.
FASEB JOURNAL (2020)
Establishment of a pancreatic adenocarcinoma molecular gradient (PAMG) that predicts the clinical outcome of pancreatic cancer
Remy Nicolle et al.
EBIOMEDICINE (2020)
PDX-derived organoids model in vivo drug response and secrete biomarkers
Ling Huang et al.
JCI INSIGHT (2020)
Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma
Benedikt Kaufmann et al.
DIGESTIVE SURGERY (2019)
Pancreatic cancer: a growing burden
Alison P. Klein
LANCET GASTROENTEROLOGY & HEPATOLOGY (2019)
Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors
Prashanth Rawla et al.
WORLD JOURNAL OF ONCOLOGY (2019)
The challenge of drug resistance in pancreatic ductal adenocarcinoma: a current overview
Francisco Quinonero et al.
CANCER BIOLOGY & MEDICINE (2019)
Patient Derived Xenografts (PDX) for personalized treatment of pancreatic cancer: emerging allies in the war on a devastating cancer?
Sereti Evangelia et al.
JOURNAL OF PROTEOMICS (2018)
Genetic and transcriptional evolution alters cancer cell line drug response
Uri Ben-David et al.
NATURE (2018)
Familial Pancreatic Cancer
Julia Benzel et al.
ONCOLOGY RESEARCH AND TREATMENT (2018)
Targeted Therapies for Pancreatic Cancer and Hurdles Ahead
Minela Aslan et al.
ANTICANCER RESEARCH (2018)
Stratification of Pancreatic Ductal Adenocarcinomas Based on Tumor and Microenvironment Features
Francesco Puleo et al.
GASTROENTEROLOGY (2018)
Neoadjuvant Therapy of Pancreatic Cancer: Definitions and Benefits
Stefan Heinrich et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenografts
Remy Nicolle et al.
CELL REPORTS (2017)
Genomic analyses identify molecular subtypes of pancreatic cancer
Peter Bailey et al.
NATURE (2016)
Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs
Marc Hafner et al.
NATURE METHODS (2016)
Transcriptomic Analysis Predicts Survival and Sensitivity to Anticancer Drugs of Patients with a Pancreatic Adenocarcinoma
Pauline Duconseil et al.
AMERICAN JOURNAL OF PATHOLOGY (2015)
Addressing the challenges of pancreatic cancer: Future directions for improving outcomes
Manuel Hidalgo et al.
PANCREATOLOGY (2015)
Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy
Eric A. Collisson et al.
NATURE MEDICINE (2011)
Share Paper
